|
| Status |
Public on Dec 17, 2021 |
| Title |
Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jan 06, 2020 |
| Last update date |
Dec 17, 2021 |
| Contact name |
Matthew Nix |
| E-mail(s) |
matthew.nix@ucsf.edu
|
| Organization name |
UCSF
|
| Department |
Laboratory Medicine
|
| Street address |
185 Berry St
|
| City |
San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94107 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (21)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE142447 |
Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I |
| GSE143179 |
Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies II |
|
| Relations |
| BioProject |
PRJNA599148 |
Less...
More...